CompuCyte and Genetics Institute to develop theranostics:
This article was originally published in Clinica
CompuCyte and Genetics Institute (GI) are to collaborate on developing diagnostic tests that help select patients for drug therapy and follow them during treatment - so-called theranostics. Under the agreement, CompuCyte will develop cell-based assays for monitoring the effects of drugs known as cell adhesion inhibitors. GI, a unit of American Home Products' pharmaceutical division Wyeth-Ayerst Laboratories, is developing cell adhesion inhibitors to treat vascular and inflammatory diseases. The assays will be performed with Compuctye's OneCyte laser scanning technology.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.